Alto Neuroscience, Inc. Operating Expenses
Alto Neuroscience, Inc. (ANRO) reported Operating Expenses of $29.13 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-12
- Alto Neuroscience, Inc. operating expenses for the quarter ending 2026-06-30 was $29.13M, a 55.92% increase year-over-year.
- Alto Neuroscience, Inc. operating expenses for the quarter ending 2026-03-31 was $27.14M, a 73.12% increase year-over-year.
- Alto Neuroscience, Inc. operating expenses for the quarter ending 2025-12-31 was $17.05M, a 0.34% increase year-over-year.
- Alto Neuroscience, Inc. operating expenses for the quarter ending 2025-09-30 was $14.95M, a 20.84% decline year-over-year.
- Alto Neuroscience, Inc. operating expenses for fiscal 2025 was $66.36M, a 3.27% decline from fiscal 2024.
- Alto Neuroscience, Inc. operating expenses for fiscal 2024 was $68.61M, a 81.46% increase from fiscal 2023.
- Alto Neuroscience, Inc. operating expenses for fiscal 2023 was $37.81M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $29.13M 10-Q · filed 2026-08-12 | $56.27M 10-Q · filed 2026-08-12 | $73.32M derived: sum of 3 quarters · filed 2026-08-12 | $88.27M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $27.14M 10-Q · filed 2026-05-13 | $44.19M derived: sum of 2 quarters · filed 2026-05-13 | $59.14M derived: sum of 3 quarters · filed 2026-05-13 | $77.83M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $17.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $32.01M derived: sum of 2 quarters · filed 2026-03-16 | $50.69M derived: sum of 3 quarters · filed 2026-08-12 | $66.36M 10-K · filed 2026-03-16 |
| 2025-09-30 | $14.95M 10-Q · filed 2025-11-12 | $33.63M derived: sum of 2 quarters · filed 2026-08-12 | $49.31M 10-Q · filed 2025-11-12 | $66.31M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $18.68M 10-Q · filed 2026-08-12 | $34.36M 10-Q · filed 2026-08-12 | $51.35M derived: sum of 3 quarters · filed 2026-08-12 | $70.24M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $15.68M 10-Q · filed 2026-05-13 | $32.67M derived: sum of 2 quarters · filed 2026-05-13 | $51.56M derived: sum of 3 quarters · filed 2026-05-13 | $69.90M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $35.88M derived: sum of 2 quarters · filed 2026-03-16 | $54.22M derived: sum of 3 quarters · filed 2026-03-16 | $68.61M 10-K · filed 2026-03-16 |
| 2024-09-30 | $18.89M 10-Q · filed 2025-11-12 | $37.23M derived: sum of 2 quarters · filed 2025-11-12 | $51.61M 10-Q · filed 2025-11-12 | $63.38M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $18.34M 10-Q · filed 2025-08-13 | $32.73M 10-Q · filed 2025-08-13 | $44.49M derived: sum of 3 quarters · filed 2025-08-13 | $54.21M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $14.39M 10-Q · filed 2025-05-14 | $26.15M derived: sum of 2 quarters · filed 2025-05-14 | $35.87M derived: sum of 3 quarters · filed 2025-05-14 | $44.99M derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $11.77M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $21.48M derived: sum of 2 quarters · filed 2025-03-20 | $30.61M derived: sum of 3 quarters · filed 2025-03-20 | $37.81M 10-K · filed 2025-03-20 |
| 2023-09-30 | $9.72M 10-Q · filed 2024-11-12 | $18.84M derived: sum of 2 quarters · filed 2024-11-12 | $26.04M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | $9.13M 10-Q · filed 2024-08-13 | $16.33M 10-Q · filed 2024-08-13 | ||
| 2023-03-31 | $7.20M 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |